
A study focused on the role of cancer stem cell-like cells (CSCs) in head and neck squamous cell carcinoma (HNSCC) found that a gene called LIMP-2 could serve as a therapeutic target for regulating HNSCC progression and CSC properties. High expression of LIMP-2 was associated with a poor prognosis and potential resistance to immunotherapy in HNSCC patients. The study also discovered that LIMP-2 facilitates the formation of autolysosomes, thereby promoting autophagic flux. Knocking down LIMP-2 inhibited autophagic flux and reduced the tumorigenic ability of HNSCC. Additionally, the researchers found that enhanced autophagy helps HNSCC maintain stemness and promotes the degradation of GSK3β, leading to the translocation of β-catenin into the nucleus and the transcription of downstream target genes. These findings suggest that LIMP-2 could be a promising therapeutic target for HNSCC, and they establish a connection between autophagy, CSCs, and immunotherapy resistance in this cancer type.
Like
Save
Share